Factor Xa (FXa) is well known to play a pivotal role in blood coagulation, so FXa inhibitor is a promising drug candidate for prophylaxis and treatment of thromboembolic diseases. In the course of our research, we have found that (R)-5-[1-(acetimidoyl)piperidin-4-yloxy]-2-(7-amidinonaphthalen-2-yl) -1-(ethanesulfonyl)indoline ((R)-1) showed potent FXa inhibitory activity in vitro. However, single oral administation (RS)-1 showed high toxicity in mice. Among newly synthesized compounds, ({(RS)-5-[1-(acetimidoyl)piperidin-4-yloxy]- 2-(7-amidinonaphthalen-2-yl)indolin-1-yl}sulfonyl)acetic acid ((RS)-11d) showed more potent FXa inhibitory activity and higher safety than (RS)-1. The R-isoform of compound 11d ((R)-11d) exhibited potent in vitro anticoagulant activity in human and hamster plasma. Orally administered (R)-11d also showed dose-dependent potent anticoagulant activity in hamsters, marmosets and cynomolgus monkeys. Compound (R)-11d with potent anticoagulant activity and high safety is therefore favorable as a novel oral FXa inhibitor. © 2007 Pharmaceutical Society of Japan.
CITATION STYLE
Noguchi, T., Tanaka, N., Nishimata, T., Goto, R., Hayakawa, M., Sugidachi, A., … Fujimoto, K. (2007). Indoline derivatives II: Synthesis and factor Xa (FXa) inhibitory activities. Chemical and Pharmaceutical Bulletin, 55(3), 393–402. https://doi.org/10.1248/cpb.55.393
Mendeley helps you to discover research relevant for your work.